Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics, with news centered on its approved medicines, TTR franchise, clinical pipeline and financial performance. Company updates commonly address AMVUTTRA/vutrisiran and ONPATTRO/patisiran for transthyretin-mediated amyloidosis, GIVLAARI/givosiran for acute hepatic porphyria, OXLUMO/lumasiran for primary hyperoxaluria type 1, and partner-commercialized RNAi medicines.
Recurring developments include quarterly product revenue reports, guidance, clinical and real-world data for ATTR-CM and other cardiovascular programs, pipeline progress across cardio-metabolic disease, neuroscience and hematology, disease-awareness collaborations, and investor conference presentations. Alnylam also reports on its Alnylam 2030 strategy and commercialization of RNAi medicines in global markets.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported positive interim results from its Phase 1 study of ALN-AGT, a novel RNAi therapeutic for hypertension. The study showed significant dose-dependent reductions in serum angiotensinogen (AGT) and blood pressure, with a maximum 17 mm Hg reduction in 24-hour systolic blood pressure at the 800 mg dose. The treatment was well tolerated, with most adverse events being mild. The company plans to initiate Phase 2 KARDIA studies in mid-2021, suggesting ALN-AGT may transform hypertension management.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present an overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 1:30 pm ET. A live audio webcast will be accessible via the Investors section of the Company's website, with a replay available within 48 hours post-event. Alnylam is a leader in RNA interference (RNAi) therapeutics, aiming to transform treatments for rare genetic, cardio-metabolic, hepatic infectious, and CNS diseases. Their portfolio includes commercially available products like ONPATTRO, GIVLAARI, OXLUMO, and Leqvio.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced pivotal results from the ILLUMINATE-A Phase 3 study of lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1 (PH1). Published in NEJM, the study showed a significant 53.5% reduction in urinary oxalate levels compared to placebo at six months. Notably, 84% of patients on lumasiran reached normal or near-normal oxalate levels. The treatment had a favorable safety profile with no severe adverse events reported. OXLUMO is the first approved therapy for PH1, addressing a critical unmet medical need for patients.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present a company overview at the Stifel 3rd Annual CNS Day on April 1, 2021, at 11:00 am ET. A live audio webcast will be accessible via the Investors section of Alnylam's website, with a replay available within 48 hours. Alnylam is a leader in RNA interference therapeutics, focusing on innovative medicines for rare genetic and CNS diseases. They have launched products like ONPATTRO and are advancing multiple investigational medicines under the Alnylam P5x25 strategy.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced the upcoming presentation of full 9-month results from the HELIOS-A Phase 3 study of vutrisiran at the AAN Virtual Annual Meeting, scheduled for April 17-22. Vutrisiran is an investigational RNAi therapeutic for hereditary ATTR amyloidosis. This milestone follows the positive topline results previously reported in January. The company aims to submit a U.S. regulatory filing for vutrisiran in early 2021. The presentation will also feature updates from ongoing studies on ONPATTRO and GIVLAARI.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has published its first Corporate Responsibility (CR) Summary, outlining its environmental, social, and governance (ESG) standards. Key commitments include increasing minority participation in clinical trials, promoting female leadership, and enhancing employee support programs. The report emphasizes Alnylam's dedication to sustainability and accountability, led by a new CR Committee. It marks a significant step toward the company's vision of becoming a top 5 biotech firm while adhering to its core values.
Soleo Health has joined the treatment center directory for GIVLAARI (givosiran), enabling it to administer this FDA-approved therapy for adults with Acute Hepatic Porphyria (AHP). GIVLAARI is the first approved treatment for AHP, which causes the buildup of neurotoxins. Soleo Health offers injections in-home or at its infusion centers, utilizing its experience in specialty pharmacy. This partnership enhances Soleo's portfolio in treating rare diseases and utilizes SoleMetrics to collect valuable patient data over time.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at three upcoming virtual conferences. The events are the Cowen 41st Annual Healthcare Conference on March 1 at 2:40 pm ET, the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 am ET, and the Barclays Global Healthcare Conference on March 10 at 1:15 pm ET. Each presentation will have a live audio webcast available on the Company’s website, with replays accessible within 48 hours.
Alnylam specializes in RNA interference therapeutics aimed at treating various severe diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a company overview presentation at the 10th Annual SVB Leerink Global Healthcare Conference, scheduled for February 25, 2021, at 11:20 am ET. A live audio webcast will be accessible on the Investors section of Alnylam's website, with a replay available 48 hours post-event.
Alnylam is a leader in RNA interference therapeutics, developing innovative medicines for various diseases. Its current products include ONPATTRO, GIVLAARI, and OXLUMO, among others.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported strong financial results for Q4 and full year 2020, showcasing significant growth in product revenues amid regulatory approvals. ONPATTRO achieved $306 million in annual revenue, marking over 80% growth from 2019, while GIVLAARI brought in $55 million in its launch year. The company expects combined 2021 product revenues between $610 million and $660 million, indicating over 75% growth from 2020. Key developments included positive Phase 3 results for vutrisiran and the launch of OXLUMO. Alnylam anticipates continued expansion and product launches in 2021.